AVITA Medical, Inc. (RCEL) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$10.99

From 52W high−1.78%

Volume356656.00

Market cap$340.81M

P/E (TTM)—

P/S (TTM)4.5x

Div yield—

Key dataSep 18, 2026

Open

$10.99

From 52W high

−1.78%

Volume

356656.00

Market cap

$340.81M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.0x

P/E (TTM)

—

RSI (14)

66.6

MomentumView details →

1D Return

−1.78%

YTD Return

+218.64%

SummaryUpdated Jun 1, 2026

AVITA Medical, Inc. (NASDAQ:RCEL) is a commercial-stage regenerative medicine company founded in 2000 and based in Valencia, California. The company specializes in developing and commercializing innovative tissue regeneration products that harness the healing properties of a patient's own skin. Originally incorporated as AVITA Therapeutics, Inc., the company rebranded to AVITA Medical Inc. in December 2020 and went public in 2012. AVITA has evolved from a single-product company focused on burn treatment to a multi-product acute wound care company serving hospitals and medical centers across the United States, with expanding international operations in Europe, Australia, and Japan.

Ask drillr about AVITA Medical, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.0x

EV/Sales

5.0x

P/S (TTM)

4.5x

P/B (TTM)

−12.2x

ProfitabilityView details →

Gross Margin

81.56%

Net Margin

−56.96%

EBITDA Margin

−45.52%

ROE (TTM)

154.76%

ROA (TTM)

−90.17%

Asset Turnover

1.52x

GrowthView details →

Revenue YoY

+1.00%

EPS YoY

+26.40%

FCF YoY

+43.88%

Revenue CAGR 3Y

+27.66%

EPS CAGR 3Y

+27.20%

EBITDA YoY

+22.88%

MomentumView details →

1D Return

−1.78%

YTD Return

+218.64%

1Y Return

+100.97%

RSI (14)

66.6

vs 50D SMA

+42.29%

vs 200D SMA

+117.37%

Capital & dividendView details →

Debt/Equity

−1.74x

Current Ratio

0.41x

Quick Ratio

0.34x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.25

EPS Surprise

14.62%

Beats (12Q)

4/12

Next Q EPS Est

−$0.24

Avg Surprise (4Q)

24.75%

Rev Surprise

6.98%

Financials snapshotView financials →

Revenue (TTM)

75.63M

Net Income (TTM)

−43.08M

Op. CF (TTM)

−24.23M

Next earningsNov 5, 2026 →

Latest newsMore news →

AVITA Medical raised its 2026 revenue guidance to $86 million-$89 million from $80 million-$85 million at the Morgan Stanley 24th Annual Global Healthcare Conference.4d ago

AVITA Medical announced positive study results for its PermeaDerm product, demonstrating a 70% economic advantage over allograft and comparable clinical outcomes.33d ago

Similar companies

Viemed Healthcare, Inc.VMD Broncus Holding Corporation02216.HK Orthofix Medical Inc.OFIX Austar Lifesciences Limited06118.HK TriSalus Life Sciences, Inc.TLSI Suzhou Basecare Medical Corporation Limited02170.HK Find similar companies →

Latest newsMore news →

AVITA Medical raised its 2026 revenue guidance to $86 million-$89 million from $80 million-$85 million at the Morgan Stanley 24th Annual Global Healthcare Conference.4d ago AVITA Medical announced positive study results for its PermeaDerm product, demonstrating a 70% economic advantage over allograft and comparable clinical outcomes.33d ago